APO RESEARCH · REPORT
Hemophilia Gene Therapy
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
Product & engineering
Understand the product.
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
Selected research
Industry Research
Hemophilia Gene Therapy Industry Research Report 2026
Market perspective
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
Report Scope
Read the full market overview
This report quantifies the global Hemophilia Gene Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Hemophilia Gene Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hemophilia Gene Therapy Market by Company
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics
Hemophilia Gene Therapy Segment by Type
Hemophilia A
Hemophilia B
Hemophilia Gene Therapy Segment by Application
Hemophilia A Gene Therapy
Hemophilia B Gene Therapy
Hemophilia Gene Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Hemophilia Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hemophilia A
- Hemophilia B
Applications
- Hemophilia A Gene Therapy
- Hemophilia B Gene Therapy
Companies covered
- Spark Therapeutics
- Ultragenyx
- Shire PLC
- Sangamo Therapeutics
- Bioverativ
- BioMarin
- uniQure
- Freeline Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Hemophilia Gene Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Hemophilia A
- 2.2.3 Hemophilia B
- 2.3 Hemophilia Gene Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hemophilia A Gene Therapy
- 2.3.3 Hemophilia B Gene Therapy
- 2.4 Assumptions and Limitations
3 Hemophilia Gene Therapy Breakdown Data by Type
- 3.1 Global Hemophilia Gene Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Hemophilia Gene Therapy Forecasted Market Size by Type (2027-2032)
4 Hemophilia Gene Therapy Breakdown Data by Application
- 4.1 Global Hemophilia Gene Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Hemophilia Gene Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Hemophilia Gene Therapy Market Perspective (2021-2032)
- 5.2 Global Hemophilia Gene Therapy Growth Trends by Region
- 5.2.1 Global Hemophilia Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Hemophilia Gene Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Hemophilia Gene Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Hemophilia Gene Therapy Market Dynamics
- 5.3.1 Hemophilia Gene Therapy Industry Trends
- 5.3.2 Hemophilia Gene Therapy Market Drivers
- 5.3.3 Hemophilia Gene Therapy Market Challenges
- 5.3.4 Hemophilia Gene Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Hemophilia Gene Therapy Players by Revenue
- 6.1.1 Global Top Hemophilia Gene Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Hemophilia Gene Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Hemophilia Gene Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Hemophilia Gene Therapy Head Office and Area Served
- 6.4 Global Hemophilia Gene Therapy Players, Product Type & Application
- 6.5 Global Hemophilia Gene Therapy Manufacturers Established Date
- 6.6 Global Hemophilia Gene Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Hemophilia Gene Therapy Market Size (2021-2032)
- 7.2 North America Hemophilia Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Hemophilia Gene Therapy Market Size by Country (2021-2026)
- 7.4 North America Hemophilia Gene Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Hemophilia Gene Therapy Market Size (2021-2032)
- 8.2 Europe Hemophilia Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Hemophilia Gene Therapy Market Size by Country (2021-2026)
- 8.4 Europe Hemophilia Gene Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Hemophilia Gene Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Hemophilia Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Hemophilia Gene Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Hemophilia Gene Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Hemophilia Gene Therapy Market Size (2021-2032)
- 10.2 South America Hemophilia Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Hemophilia Gene Therapy Market Size by Country (2021-2026)
- 10.4 South America Hemophilia Gene Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Hemophilia Gene Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Hemophilia Gene Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Spark Therapeutics
- 12.1.1 Spark Therapeutics Company Information
- 12.1.2 Spark Therapeutics Business Overview
- 12.1.3 Spark Therapeutics Revenue in Hemophilia Gene Therapy Business (2021-2026)
- 12.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
- 12.1.5 Spark Therapeutics Recent Developments
- 12.2 Ultragenyx
- 12.2.1 Ultragenyx Company Information
- 12.2.2 Ultragenyx Business Overview
- 12.2.3 Ultragenyx Revenue in Hemophilia Gene Therapy Business (2021-2026)
- 12.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
- 12.2.5 Ultragenyx Recent Developments
- 12.3 Shire PLC
- 12.3.1 Shire PLC Company Information
- 12.3.2 Shire PLC Business Overview
- 12.3.3 Shire PLC Revenue in Hemophilia Gene Therapy Business (2021-2026)
- 12.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
- 12.3.5 Shire PLC Recent Developments
- 12.4 Sangamo Therapeutics
- 12.4.1 Sangamo Therapeutics Company Information
- 12.4.2 Sangamo Therapeutics Business Overview
- 12.4.3 Sangamo Therapeutics Revenue in Hemophilia Gene Therapy Business (2021-2026)
- 12.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
- 12.4.5 Sangamo Therapeutics Recent Developments
- 12.5 Bioverativ
- 12.5.1 Bioverativ Company Information
- 12.5.2 Bioverativ Business Overview
- 12.5.3 Bioverativ Revenue in Hemophilia Gene Therapy Business (2021-2026)
- 12.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
- 12.5.5 Bioverativ Recent Developments
- 12.6 BioMarin
- 12.6.1 BioMarin Company Information
- 12.6.2 BioMarin Business Overview
- 12.6.3 BioMarin Revenue in Hemophilia Gene Therapy Business (2021-2026)
- 12.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
- 12.6.5 BioMarin Recent Developments
- 12.7 uniQure
- 12.7.1 uniQure Company Information
- 12.7.2 uniQure Business Overview
- 12.7.3 uniQure Revenue in Hemophilia Gene Therapy Business (2021-2026)
- 12.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
- 12.7.5 uniQure Recent Developments
- 12.8 Freeline Therapeutics
- 12.8.1 Freeline Therapeutics Company Information
- 12.8.2 Freeline Therapeutics Business Overview
- 12.8.3 Freeline Therapeutics Revenue in Hemophilia Gene Therapy Business (2021-2026)
- 12.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
- 12.8.5 Freeline Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst